LABNET - RAPIDLY DEPLOYABLE AUTONOMOUS LABORATORY

实验室自动化是一项关键创新，可以帮助克服2020年COVID-19大流行对社交距离的要求。虽然自动化仪器已经在高通量环境中使用了几十年，但它们还没有过渡到常规的实验室研究。此外，目前的实验室自动化缺乏机器学习和人工智能，这些可以帮助指导基于实时分析的实验设计。拟议项目的总体目标是开发和商业化可扩展的软件和硬件系统LABNET，该系统将集成人工智能（AI）工具、用于数据传输和存储的自主和模块化实验室仪器，以及用于实验室研究的多尺度和机器学习（MS-ML）建模和分析的云计算。第一阶段将侧重于系统的设计和演示，以执行自动化ELISA检测，该检测将由AI工具套件指导，使用商用现成的液体处理系统快速筛选抗体。第二阶段将专注于附加仪器、生物测定和高通量仪器的集成。开发的产品将商业化给制药公司、生物技术公司、研究实验室、大学和参与分析开发、分子诊断和药物发现的非营利组织。

Laboratory automation is a key innovation that can help overcome the social distancing requirements due to the 2020 COVID-19 pandemic. Although, automation instruments have been used for decades in high throughput settings, they have not transitioned to routine laboratory research. Moreover, current laboratory automation lacks machine learning and artificial intelligence that can help guide design of experiments based on real-time analytics. The overall goal of the proposed project is to develop and commercialize a scalable software and hardware system, LABNET, which will integrate artificial intelligence (AI) tools, autonomous and modular laboratory instruments for data transmission and storage, and cloud computing for multi-scale and machine-learning (MS-ML) modeling and analytics for laboratory research. Phase I will focus on design and demonstration of the system to perform automated ELISA assays which will be guided by AI suite of tools for rapid screening of antibodies using a commercial off-the-shelf liquid handling system. Phase II will focus on integration of additional instrumentation, biological assays and high throughput instrumentation. The developed product will be commercialized to pharmaceutical, biotech companies, research labs, universities and non-profit organizations involved in assay development, molecular diagnostics and drug discovery.